Evidence map›Paper›PMID 35155856›Full record

ReviewKidney international reports2022

Incremental Versus Standard (Full-Dose) Peritoneal Dialysis.

Melissa S Cheetham, Yeoungjee Cho, Rathika Krishnasamy, Arsh K Jain, Neil Boudville, David W Johnson, Louis L Huang

Open access · goldAbstract readReview
In one paragraph

Review in Kidney international reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
4.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Observational
  5. Article
  6. Article
  7. Article
  8. Article
  9. Observational
  10. Review
  11. Article
  12. Article
  13. Article
  14. Five Things to Know About Incremental Peritoneal Dialysis.Canadian journal of kidney health and disease · 2023
    Article
  15. Review
  16. Outcomes of incident patients treated with incremental haemodialysis as compared with standard haemodialysis and peritoneal dialysis.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2022
    Article
  17. Review
  18. Article
  19. Peritoneal dialysis: why not?Jornal brasileiro de nefrologia
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 2 countries.

Melissa S CheethamDepartment of Nephrology, Sunshine Coast University Hospital, Birtinya, Australia.
Yeoungjee ChoFaculty of Medicine, The University of Queensland, Brisbane, Australia.
Rathika KrishnasamyDepartment of Nephrology, Sunshine Coast University Hospital, Birtinya, Australia.
Arsh K JainSchulich School of Medicine & Dentistry, Department of Epidemiology & Biostatistics, Western University, London, Canada.
Neil BoudvilleMedical School, University of Western Australia, Perth, Australia.
David W JohnsonFaculty of Medicine, The University of Queensland, Brisbane, Australia.
Louis L HuangDepartment of Renal Medicine, Eastern Health Clinical School, Monash University, Melbourne, Australia.
The University of Queensland · AUTranslational Research Institute · AUEastern Health · AUThe University of Western Australia · AUWestern University · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Incremental peritoneal dialysis (PD), defined as less than "standard dose" PD prescription, has a number of possible benefits, including better preservation of residual kidney function (RKF), reduced risk of peritonitis, lower peritoneal glucose exposure, lesser environmental impact, and reduced costs. Patients commencing PD are often new to kidney replacement therapy and possess substantial RKF, which may allow safe delivery of an incremental prescription, often in the form of lower frequency or duration of PD. This has the potential to help improve quality of life (QOL) and life participation through reducing time requirements and burden of treatment. Alternatively, incremental PD could potentially contribute to reduced small solute clearance, fluid overload, or patient reluctance to increase dialysis prescription when later needed. This review discusses the definition, rationale, uptake, potential advantages and disadvantages, and clinical trial evidence pertaining to the use of incremental PD.

Indexed as

incremental dialysispatient-centered careperitoneal dialysispersonalized medicinequality of life

Identifiers

PMID35155856
PMCPMC8820986
OpenAlexW3217032967

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.